China’s non-invasive colon cancer screening biotech company, New Horizon Health Limited, announced in a signing ceremony that it had an agreement with Prenetics Limited, a genetic and digital health company in Asia and Europe, to launch a non-invasive multi-target stool DNA test for colorectal cancer called ColoClear.
ColoClear is a non-invasive screening test for individuals who are at risk of developing colon cancer. It is specifically developed for individuals who are of Asian ethnicity and have been validated through clinical studies to perform at 92% sensitivity in the detection of colon cancer.
Under the terms of the agreement, New Horizon will provide a technical transfer to Prenetics for ColoClear. The agreement calls for that Prenetics will set up a dedicated facility in its ISO-15189 accredited Hong Kong laboratory to begin commercialization services for Hong Kong in early 2020 and for Southeast Asia later in the year.
Zhu Yeqing, chief executive officer of New Horizon, said, "since company inception in 2013, our mission is to make our technology available to as many people as possible throughout Asia in the fight against Colon Cancer. With ColoClear, we have now validated through multi-center clinical studies that it is the leading non-invasive colon cancer stool DNA test in the market here in Asia. We are extremely excited to partner with Prenetics for the technical transfer and commercialization of ColoClear in Hong Kong and Southeast Asia."
Danny Yeung, chief executive officer of Prenetics, stated, "Colon Cancer is one of the most common cancers in Hong Kong and Southeast Asia. It is also most often diagnosed at too late a stage and one which is highly preventable with early detection. With ColoClear, it is a true technological Game Changer in terms of performance and can be accessible by millions of people in the region. Through our initial market research, we have already received immensely positive responses from Insurers, clinics, hospitals, and consumers on ColoClear. Together with New Horizon, we look to significantly reduce both the mortality and incidence rate of Colon Cancer in the region."
Founded in 2013, New Horizon Health is a biotechnology company focused on the development of innovative products for the early detection of cancer with emphasis on GI and lung cancer.